A phase 2 trial evaluating the 2 checkpoint inhibitors, nivolumab and ipilimumab, found significantly better tumor responses with the combination compared with nivolumab alone in patients with ...

In the ipilimumab-monotherapy group, the same dosing schedule was used, except that nivolumab was replaced with matched placebo during both the combination and maintenance portions of the trial.

Ipilimumab is an effective treatment for melanoma; however, toxicity rates remain high. The objective of this study was to describe the rates of adverse events (AEs), emergency room (ER) visits, ...

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors Eligibility criteria ...

Credit: Getty Images. The CheckMate -914 trial included patients with localized RCC who underwent radical or partial nephrectomy and who were at high risk of relapse. A phase 3 study evaluating ...

The full Prescribing Information for YERVOY includes a boxed warning for immune-mediated adverse reactions. YERVOY can result in severe and fatal immune-mediated adverse reactions due to T-cell ...

A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...

Study 024 Evaluated Newly-Diagnosed Patients Treated with YERVOY at Investigational Dose of 10mg/kg in Combination with Dacarbazine vs. Dacarbazine Alone Forty-Seven Percent of Patients Treated with ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab plus ipilimumab induced durable responses among a subset of men with metastatic castration-resistant ...

Please provide your email address to receive an email when new articles are posted on . Combination therapy with nivolumab plus ipilimumab conferred an OS benefit for patients with asymptomatic ...